Fitch Ratings upgraded its credit grade on both Bausch + Lomb Corp. and its parent company Bausch Health Cos., but said the ...

Bausch + Lomb issued the recall after the company received reports of toxic anterior segment syndrome, or an inflammatory ...

LAVAL, QC / ACCESS Newswire / April 14, 2025 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) (the "Company" or "Bausch ...

Bausch Health Companies (BHC) and its gastroenterology business, Salix Pharmaceuticals, announced the U.S. District Court for the District of ...

The eye health company Bausch + Lomb announced on Monday that it is recalling several of its intraocular lenses due to safety ...

Bausch + Lomb, a leading global eye health company, announced a voluntary recall of its Envista Aspire, Envista Envy and ...

Bausch + Lomb is recalling intraocular lenses (IOLs) on its enVista platform. This action was taken after the company ...

Bausch Health's Aplenzin could revolutionize TRD care, addressing a $3B market opportunity while aiding BHC stock's financial ...

NEW YORK CITY, NY / ACCESS Newswire / April 11, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims ...

Investing.com -- Bausch Health Companies Inc (NYSE: BHC) stock closed up 13.3% following a favorable court decision. The U.S. District Court for the District of Columbia ruled in favor of the company ...

HealthDay News — Bausch + Lomb has announced a voluntary recall of intraocular lenses on its enVista platform due to the potential for an acute postoperative inflammatory reaction.

Looking back on medical devices & supplies - specialty stocks’ Q4 earnings, we examine this quarter’s best and worst ...